Supplemental Information Regarding the Special Meeting of Stockholders to be Held on August 12, 2024
On July 8, 2024 Vincerx Pharma, Inc. (the Company) filed with the Securities and Exchange Commission (the SEC) and
provided to its stockholders of record as of July 2, 2024 a definitive proxy statement (the Proxy Statement) describing the matters to be voted on at a Special Meeting of Stockholders, to be held on August 12, 2024 at 10:00
a.m. Pacific Time via live audio webcast (the Special Meeting).
This supplement, dated August 2, 2024 (the Supplement), updates
the Proxy Statement to reflect certain updates the Company is making to the terms of the proposed Repricing and Exchange Program, to, among other things, (i) lengthen the vesting schedule that will apply to RSUs to be granted in exchange for
Eligible Options tendered in the Exchange; (ii) provide that the Repriced Option Retention Period will end early if an optionholder is terminated without cause; and (iii) address the possibility that some Eligible Options may not be
subject to the Repricing as a result of changes in our stock price. Terms used in this Supplement, but not otherwise defined, shall have the meanings ascribed to such terms in the Proxy Statement.
This Supplement amends and restates in their entirety the subsections set forth below, each of which were included in the Proxy Statement under
Proposal 1: Approval of Stock Option Repricing and Exchange Program.
Repricing and Exchange Program
Structure
Our board of directors, based on the
recommendation of our compensation committee (Compensation Committee), approved, subject to the approval of our stockholders at the Special Meeting, the Repricing and Exchange Program. If approved by stockholders, the exercise price per
share of Eligible Options (as defined below) having an exercise price per share greater than the closing price of our common stock on the Nasdaq Capital Market (Nasdaq) on the date of the Special Meeting (the Repricing Date)
would be reduced (the Repricing) to an amount equal to one hundred percent (100%) of the closing price of our common stock on Nasdaq on the Repricing Date, rounded up to the nearest penny (the Repriced Exercise Price). There
will be no changes to the number of shares underlying the repriced options (the Repriced Options) or the vesting schedule or expiration dates of the Repriced Options.
Following the Repricing Date, we anticipate commencing an offer for eligible participants to surrender their Eligible Options in exchange for the grant under
the Incentive Plan of RSUs that may be settled for shares of our common stock (the Exchange), with the number of RSUs granted determined based on an Exchange Ratio (as defined below).
Eligible Participants
Our current employees
(including executive officers) and our current consultants (solely for purposes of this proposal defined as employees) who hold Eligible Options will be eligible to participate in the Repricing and Exchange Program. Our non-employee directors will not be eligible to participate. To be eligible for the Repricing, an employee must remain employed with the Company, or otherwise continue to provide services to the Company as a
consultant, through the Repricing Date. To be eligible for the Exchange, an employee must be employed with the Company, or otherwise continue to provide services to the Company as a consultant, both at the time the Exchange commences and at the time
RSUs are granted following completion of the Exchange. Employees who satisfy these criteria are referred to as Eligible Participants.
Eligible Options
All outstanding, non-exercised stock options held by an Eligible Participant as of the date of the Special Meeting will be eligible for the Repricing, and all outstanding, non-exercised stock
options held by Eligible Participants upon completion of the Exchange will be eligible for the Exchange (as applicable, the Eligible Options).